Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
Cancers|April 14, 2025
Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE StudyAnna Sureda, Ramón García-Sanz, Eva Domingo-Domenech, et al.
Journal of Clinical Medicine|June 27, 2024
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient RegistryDeborah Elstein, Nadia Belmatoug, Bruno Bembi, et al.
Haematologica|June 2, 2016
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialHaifa Kathrin Al-Ali, Martin Griesshammer, Philipp le Coutre, et al.
International Journal of Hematology|March 2, 2011
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patientsAdrián Alegre, Beatriz Aguado, Pilar Giraldo, et al.
Blood Cells, Molecules & Diseases|October 12, 2010
Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortagePilar Giraldo, Pilar Irún, Pilar Alfonso, et al.
British Journal of Haematology|March 5, 2020
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progressionAscensión López-Díaz de Cerio, Ricardo García-Muñoz, Esther Pena, et al.
American Journal of Hematology|February 13, 2013
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseHadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, et al.
Cancer Medicine|October 2, 2019
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trialFrancisco-Javier Peñalver, José-Antonio Márquez, Soledad Durán, et al.
American Journal of Hematology|January 23, 2013
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory M Pastores, Anna Tylki-Szymanska, et al.
Biomedicines|October 28, 2023
Clinical Outcomes of Patients with Chronic Neuropathic Form of Gaucher Disease in the Spanish Real-World Setting: A Retrospective StudySinziana Stanescu, Patricia Correcher Medina, Francisco J Del Castillo, et al.
Pageof 16